Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2008

View Archived Issues

Vx-001 telomerase vaccine immunogenic in advanced solid tumor patients

Proof-of-concept trial shows potential of atiprimod in neuroendocrine carcinoma

Data on activity of XL-647 in non-small cell lung cancer accumulates

Favorable phase III results with odanacatib in postmenopausal osteoporosis

Novel antipsoriatic agents imparted in recent University of Sunderland patent

Metabasis reports positive results from phase Ib clinical trial of MB-07811

Theratechnologies reports positive results from phase III clinical trial of tesamorelin

Aplindin effective alone and in combination with dexamethasone

Bavarian reports interim data from two phase I/II studies of MVA-BN-HER2

Euro Nippon Kayaku withdraws its MAA for Spanidin

Recent patents describe novel therapeutic agents for respiratory disorders

FDA lifts clinical hold on AeroLEF and clears phase II clinical trial

FDA approves Avodart in combination with tamsulosin for enlarged prostate

CureVac enters partnership with University of Florida to develop CV-9103 in prostate cancer

Forest announces results from CANVAS I and CANVAS II phase III studies of ceftaroline

First phase II study results of CK-1827452 in patients with heart failure

Merck provides update on U.S. regulatory status for MK-0524A and MK-0524B

Avontec reports results from a phase I study of AVT-02 UE for inflammatory skin diseases

NeuroSearch reports positive results from a phase II study in adult ADHD

Pharmaxis and the FDA agree on SPA for Bronchitol phase III registration trial

Phase II trial evaluates Reolysin in combination with paclitaxel and carboplatin

Welichem Biotech completes phase IIa WBI-1001 clinical trial in atopic dermatitis

FDA approves Velcade for injection in patients with multiple myeloma

Astellas submits sNDA in Japan for Prograf in ulcerative colitis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...